A dry powder inhalation device

Abstract

The present invention discloses a dry powder inhalation device, the device includes a container for powdered medicine, the device also includes a positioner for limiting an opening position of the container, and a driving structure for opening the container at the opening position, the device is formed with an outlet connected to the opened container, through which a user can inhale powdered medicine from the opened container, the positioner is provided with an airflow restriction member located between the positioner and the outlet, the airflow restriction member is connected to the positioner and the outlet, and the airflow resistance of the dry powder inhalation device is increased. The dry powder inhalation device with an additional airflow restriction member can meet the needs of delivering different medicines and achieve a good delivery effect.

Description

1. Technical Field

[0001] The present invention relates to a dry powder inhalation device, in particular to an inhalation device which enables a user to inhale dry powder medicine. 2. Background Technology

[0002] Dry powder inhalation therapy refers to a treatment method that treats respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) by inhaling drugs into dry powder particles into the airways and lungs. The inhalation device used by the user to actively inhale dry powder particles is a key factor affecting the clinical treatment effect. There are many types of dry powder inhalation devices, which are divided into vesicle type, capsule type, and reservoir type according to the storage method of the drug.

[0003] GSK disclosed various embodiments of vesicle-type inhalation devices in patent GB2242134B, among which the embodiments of the inhalation devices shown in Figures 13-16 of the specification are the ones developed and marketed by GSK. The series of products are used as inhalation devices to deliver multiple products including fluticasone, salmeterol, fluticasone / salmeterol combination preparations, etc., providing excellent treatment options for asthma and COPD patients. The series of products are also widely used and accepted by patients due to their good performance.

[0004] The dry powder inhalers and inhalation devices for treating asthma and / or COPD that have been marketed include: The inhalation device disclosed in EP1496858A1 is a capsule-type device for delivering tiotropium bromide monohydrate preparation; The inhalation device is also in capsule form and is used to deliver anhydrous tiotropium bromide preparations; AstraZeneca developed and marketed (SE453566B), the inhalation device is a reservoir type, used to deliver budesonide preparations, formoterol preparations, and budesonide / formoterol combination preparations.

[0005] Although these products treat the same disease, the drugs delivered by the inhalation devices are different, and there are differences in the active ingredients of the drugs and clinical trial data. Drug developers have conducted a lot of research on inhalation devices for different drugs. Studies have shown that certain performance parameters of inhalation devices, such as air flow resistance (AFR), have an important impact on the drug delivery effect of the inhalation device. The literature ("Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?" "Respiratory Medicine" 2007, 101, 2395-2401, RAMAl-Showair et al.) studied and The difference in AFR parameters of the three inhalation devices shows that at the same airflow speed, The AFR is the lowest. Highest, In the middle, different inhalation devices exhibit different AFR physical properties to meet the clinical use characteristics of the product itself. The device has been on the market for many years. Due to its excellent performance, it is widely accepted by patients. Therefore, many companies and institutions have tried to further develop it into a universal drug inhalation device, which can be used for This requires improved The device is consistent with other inhalation devices in terms of AFR.

[0006] In addition, a guideline issued by the European Medicines Agency (EMEA) entitled "Clinical documentation requirements for oral inhalation preparations, including requirements to demonstrate therapeutic equivalence between two inhalation preparations for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for the treatment of asthma in children and pre-adults" states that: For simplified applications for generic drugs, the therapeutic equivalence of the test drug and the reference drug must be demonstrated. In some cases, if the product meets all nine required criteria (compared with the reference drug), only in vitro comparative data can be used, thereby exempting clinical in vivo related studies, which can greatly shorten the time for drug clinical trials, allowing the drug to be listed as early as possible, seize the market and obtain economic benefits, which is of great significance to enterprises. Among the nine required criteria, one requirement is that the resistance to air flow (AFR) of the inhalation device of the test drug should be the same as that of the inhalation device of the reference drug, with fluctuations within the range of + / -15%.

[0007] In summary, if we want to The device was further developed into a universal inhalation device suitable for Drugs delivered by inhalation devices need to be improved device, so that its AFR and The AFR of inhalation devices is close to the same (+ / -15%), thus achieving the same drug delivery effect. At the same time, AFR is a very important one of the nine criteria for proving that the test drug and the reference drug are therapeutically equivalent. It must be consistent, thereby increasing the probability of generic drug companies being exempted from clinical in vivo research and greatly saving generic drug companies' product development time and economic costs. III. Summary of the invention

[0008] The present invention provides a dry powder inhalation device, and its invention aims to provide a dry powder inhalation device which can be used to deliver a variety of drugs.

[0009] In order to achieve the above-mentioned object, the present invention provides a dry powder inhalation device, which includes a container containing powdered medicine defined by two parts that are peelably fixed to each other, the device also includes a positioner that defines an opening position for the container, and a driving structure for peeling off the two parts at the opening position to open the container, the device is formed with an outlet connected to the opened container, through which a user can inhale powdered medicine from the opened container, the positioner is provided with an airflow restriction member located between the positioner and the outlet, the airflow restriction member is connected to the positioner and the outlet, and increases the airflow resistance (AFR) of the dry powder inhalation device.

[0010] Furthermore, the airflow restriction member is a tubular channel.

[0011] Furthermore, the tubular channel is a cylindrical tubular channel or a truncated cone tubular channel.

[0012] Furthermore, the two components are elongated sheets defining a plurality of spaced-apart drug containers along their length, wherein one sheet is a base sheet with a plurality of cavities and the other sheet is a cover sheet, each cavity and the cover sheet portion covering the cavity forming a corresponding container.

[0013] Furthermore, the device includes a main wheel with multiple grooves thereon, which engages with the drug container so that each groove accommodates a corresponding cavity, and the driving structure includes a cover driving structure and a substrate driving structure for peeling off the cover and the substrate at the opening position.

[0014] Furthermore, the main wheel and the cover drive structure and the main wheel and the substrate drive structure are connected, so that the rotation of the main wheel is related to the rotation of the cover drive structure and the substrate drive structure.

[0015] Furthermore, the positioner forms a powder outlet portion corresponding to the opening position, and an air inlet is arranged on the top of the powder outlet portion to partially cover the air inlet.

[0016] Furthermore, the powder outlet portion is formed with flow limiting holes arranged up and down on the side wall facing the opening position, and the flow limiting holes are circular holes with cross grids formed inside the circular holes.

[0017] Furthermore, a portion of the grid of the cross grid is shielded.

[0018] Furthermore, the device includes a rotating handle, which includes an arcuate wall with a finger-shaped adjustment tab and a wall extending inwardly from the arcuate wall and having a row of arcuate teeth at its terminal end, and the tail of the arcuate wall is provided with a groove for accommodating the airflow restriction member during actuation.

[0019] Furthermore, the arc-shaped wall of the rotating handle may not be provided with a groove, but the length of the arc-shaped wall should be appropriate to ensure that the airflow restriction member is not touched during the driving process. IV. Description of the drawings

[0020] Figure 1 is a top view of a dry powder inhalation device;

[0021] Figure 2 It is a schematic diagram of the partial structure inside the dry powder inhalation device;

[0022] Figure 3 is a schematic diagram of the structure of a dry powder inhalation device positioner;

[0023] Figure 4 It is a schematic diagram of the structure of the dry powder inhalation device without omitting the positioner;

[0024] Figure 5-7 It is a schematic diagram of the local structure of a dry powder inhalation device with an additional airflow restriction member;

[0025] Figure 8 It is a schematic diagram of a partial structure of a dry powder inhalation device partially blocking an air inlet;

[0026] Fig. 9 It is a schematic diagram of the local structure of the tail of the curved wall of the dry powder inhalation device. V. Specific implementation methods

[0027] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments so that those skilled in the art can understand.

[0028] Figure 1-4 Shown Dry powder inhalation device. Figure 1As shown, the dry powder inhalation device comprises a housing 1 with a cover 2, the housing 1 comprising a bottom and a top, both of which are substantially circular. When the device is assembled, the bottom and the top of the housing 1 snap together. The device is arranged below the cover 2, and the cover 2 is pivotally mounted on the housing 1 by means of a projection on the top of the housing 1 and a corresponding projection on the bottom of the housing 1 (not shown in the figure). The cover 2 pivots between an open position in which an interface member 3 is exposed and a closed position in which the interface member 3 is not exposed.

[0029] like Figure 2 As shown, the dry powder inhalation device includes a container 4 for powdered medicine defined by two parts that are fixed together in a peelable manner, and the two parts are elongated thin sheets that define a plurality of spaced medicine containers along their length, wherein one of the thin sheets is a base sheet 6 with a plurality of concave cavities 5, and the other thin sheet is a cover sheet 7 that is airtightly bonded to the base sheet 6 except for the concave cavities 5, and each concave cavity 5 and the cover sheet 7 portion covering the concave cavity 5 constitute a corresponding medicine container, and each medicine container contains a dose of powdered medicine that can be inhaled. The cover sheet 7 is airtightly bonded to the base sheet 6 in such a way that it can be peeled off from the base sheet 6. The two thin sheets are sealed to each other over their entire width except for the front end portion thereon, and the front end portions thereof are preferably not completely sealed to each other.

[0030] like Figure 2-4 As shown, the device further comprises a positioner 8 for defining an opening position of the container 4 containing the powdered medicine, and a driving structure for peeling off the two parts at the opening position to open the container 4, the driving structure comprising a cover sheet driving structure for peeling off the cover sheet 7 and the substrate 6 and a substrate driving structure, the cover sheet driving structure is a cover sheet winding wheel 11 for winding the peeled cover sheet 7, and the substrate driving structure is a substrate winding wheel 10 for winding the peeled substrate 6. The device further comprises a main wheel 9. The main wheel 9 and the cover sheet winding wheel 11 and the main wheel 9 and the substrate winding wheel 10 are connected so that the rotation of the main wheel 9 is related to the rotation of the cover sheet winding wheel 11 and the substrate winding wheel 10. The device is formed with an outlet 14 connected to the opened container 4, through which the user can inhale the powdered medicine from the opened container 4.

[0031] The positioner 8 defines four internal chambers in the housing 1. A chamber 8a is used to initially load the container 4 therein and send it out therefrom, and the positioner 8 is formed with a shaft 801 in the middle of the chamber 8a for the core of the container 4 to pass through. A chamber 8b is used to accommodate the substrate 6 after peeling, and the gear 101 of the substrate winding wheel 10 and the driven wheel 12 meshing with the gear 101 are located at the lower side of the chamber 8b. A through hole is formed in the middle of the chamber 8b, and a groove 102 of the substrate winding wheel 10 for winding the used substrate 6 passes through the through hole. A chamber 8c for accommodating the peeled cover sheet 7, in which the used cover sheet 7 is wound on a cover sheet winding wheel 11, the cover sheet winding wheel 11 is formed by two parts, namely a gear 111 with teeth 1111 and a shaft 1112 and a retracting wheel 112 with a hollow central shaft 1121 and a plurality of elastic arms 1122, for example, the retracting wheel 112 can be as follows Figure 4 Eight such arms are shown extending from a hollow central shaft 1121, each at an angle to a radius. The gear 111 has a projection which engages with a corresponding groove on the hollow central shaft 1121 so that the gear 111 and the retracting wheel 112 rotate the arms in unison. A chamber 8d is provided for placing a main wheel 9 having a plurality of grooves 901 extending parallel to its axis, the grooves 901 being spaced apart at a pitch equal to the distance between the center lines of two adjacent cavities 5, the main wheel 9 being engaged with the container 4 so that each groove 901 accommodates a corresponding cavity 5. The main wheel 9 has external teeth 902 which engage with the gear 111 of the cover film winding wheel 11 and, through the driven wheel 12, with the gear 101 of the substrate winding wheel 10. The main wheel 9 is hollow, and a ratchet is installed inside it. The ratchet teeth are formed on the inner wall of the main wheel 9, and the ratchet has two pawls meshing with the ratchet teeth, so that the main wheel 9 can only move in the counterclockwise direction, thereby ensuring that the container 4 containing the powdered medicine can only move forward through the device.

[0032] like Figure 4 As shown, the device also has a handle 13, which includes an arcuate wall 13b with a finger-shaped adjustment tab 13a and a wall 13c extending inwardly from the arcuate wall 13b and having a row of arcuate teeth 13d at its terminal end. The handle is pivotally mounted at the center of the bottom 1a of the housing so as to move about an axis at the center of the pitch circle of the teeth 13d, which mesh with the teeth on the ratchet at the bottom of the main wheel 9. In operation, the user moves the cover 2 to its open position and then presses the finger-shaped adjustment tab 13a of the handle 13 to move it with the pivoting of the handle. This operation causes the ratchet in the main wheel 9 to rotate, and this rotation causes the main wheel 9 to rotate through the pawl. The rotation of the main wheel 9 causes the rotation of both the substrate winding wheel 10 and the cover winding wheel 11, which is sufficient to peel off the substrate 6 and cover 7 of the previously unopened cavity 5 in the open position, and the user then inhales a dose of powdered medicine through the outlet 14.

[0033] The four chambers of the positioner 8 are sealed by the top of the housing (not shown). Figure 3 As shown, chamber 8a is connected to chamber 8d through channel 802, chamber 8b is connected to chamber 8d through channel 803, and chamber 8c is connected to chamber 8d through channel 804, so that the unpeeled substrate 6 and cover sheet 7 or the peeled substrate 6 and cover sheet 7 can enter and exit between different chambers. The positioner 8 is provided with a powder outlet portion 805 corresponding to the opening position of the container 4, and the powder outlet portion 805 includes an air inlet 805a at the top, and the powder outlet portion 805 is formed with flow limiting holes 805b and 805c arranged up and down on the side wall facing the opening position, and the flow limiting holes 805b and 805c are formed as circular holes, and a cross grid is formed in the circular hole, and the powder outlet portion 805 is formed with an air outlet hole 805d at the same height as the flow limiting hole 805c on the side wall facing the outlet 14. When the user inhales through the interface part 3, air flow is caused to enter the powder outlet portion 805 through the air inlet 805a, and the air flow passes through the flow limiting hole 805b and enters the opened concave cavity 5 of the container 4 containing the powdered medicine, effectively entraining the powder from the flow limiting hole 805c through the powder outlet portion 805, and finally sprayed out from the air outlet hole 805d.

[0034] If you want to The device was further developed into a universal inhalation device suitable for Drugs delivered by inhalation devices need to be improved device, so that its AFR and The airflow resistance (AFR) of the inhalation device is close to the same (+ / -15%), thus achieving the same drug delivery effect. Table 1 shows the airflow resistance (AFR) of three different devices:

[0035] Table 1:

[0036] Device DISKUS Handihaler Turbuhaler <![CDATA[Airflow resistance value ((cmH2O) 0.5 min / L)]]> 0.0873 0.1582 0.1109

[0037] visible, The airflow resistance of the dry powder inhaler is minimal. The airflow resistance of the dry powder inhaler is similar to that of other devices and needs to be increased. The airflow resistance of the dry powder inhalation device, for this reason, the present invention The components on the airflow path of the dry powder inhalation device are improved to achieve the purpose of increasing the airflow resistance, thereby achieving the same drug delivery effect.

[0038] Example 1

[0039] Using the Dry powder inhalation device delivery The drug delivered by the inhalation device is Dry powder inhalation devices are equipped with airflow restriction components, such as Figure 5 As shown, the air flow restrictor 15 is installed on the side wall of the positioner 8 facing the outlet 14, and the air flow restrictor 15 is connected with the outlet 14 and the air outlet hole 805d on the medicine outlet portion 805. The medicine powder is prepared according to US6585959B2.

[0040] Five dry powder inhalation device samples with tubular airflow restrictors of different geometrical dimensions were designed and prepared. The tubular airflow restrictors of samples No. 1 to No. 3 were cylindrical pipes, such as Figure 5 As shown, the No. 4-5 pipe is formed into a truncated cone, the cone vertex angle is 60°, and the cone is truncated at 1 / 2 of its height, as shown in FIG. Figure 6 As shown, the pipe of sample No. 4 has a small opening on one side attached to the positioner 8, as shown in FIG. Figure 7 As shown, the pipe of sample No. 5 has a larger opening on one side attached to the positioner 8. The dimensions of the pipe airflow restriction member 15 and the sample airflow resistance values ​​of the corresponding samples are shown in Table 2:

[0041] Table 2:

[0042] Sample No. 1 2 3 4 5 Handihaler Unmodified Inlet outer diameter (mm) 4.0 4.0 4.0 4.0 2 - - Inlet inner diameter (mm) 2.0 2.5 3.0 2.0 1.5 - - <![CDATA[Airflow resistance value (cmH2O) 0.5 min / L)]]> 0.1597 0.1562 0.1538 0.1668 0.1692 0.1582 0.0873

[0043] As can be seen from Table 2, by adding the airflow restriction member 15 to the positioner, the airflow resistance (AFR) of the dry powder inhaler is increased, and the requirements of The airflow resistance (AFR) of the inhalation device is close to the requirement of uniformity (+ / - 15%).

[0044] Example 2

[0045] Using the Dry powder inhalation device delivery The drug delivered by the inhalation device does not have an additional airflow restriction member, and only covers part of the air inlet 805a of the powder outlet 805 of the positioner 8 of the dry powder inhalation device. Figure 8 As shown, the drug powder is prepared according to US5674860A:

[0046] Design and prepare 5 dry powder inhalation device samples, No. 1-5 have air inlet 805a covering different areas, such as Figure 8 As shown, the shielding areas are 20%, 30%, 40%, 50%, and 60% respectively. The corresponding airflow resistance values ​​of the samples are shown in Table 3:

[0047] Table 3:

[0048] Sample No. 1 2 3 4 5 Turbuhaler Unmodified <![CDATA[Airflow resistance (cmH2O) 0.5 min / L)]]> 0.0987 0.1001 0.1013 0.1024 0.1054 0.1109 0.0873

[0049] As can be seen from Table 3, without adding an air flow restriction member, the air flow resistance (AFR) of the dry powder inhalation device can be increased by simply blocking part of the air inlet 805a at the powder outlet portion 805 of the positioner, and can meet the requirements of The airflow resistance (AFR) of the inhalation device is close to the requirement of uniformity (+ / - 15%).

[0050] Example 3

[0051] Using the Dry powder inhalation device delivery The drug delivered by the inhalation device, the flow limiting holes 805b and 805c on the locator powder outlet 805 of the dry powder inhalation device are formed as circular holes, and a cross grid is formed in the circular hole, and a baffle is formed in the grid of part of the cross grid. The preparation of the drug powder is the same as in Example 2:

[0052] Five dry powder inhalation device samples were designed and prepared. The same as Example 2, no additional airflow restriction member was provided, and only part of the flow restriction hole was blocked. No. 1-3 had flow restriction holes 805b covering different areas, and the blocked areas were 25%, 50%, and 75%, respectively. No. 4-5 had flow restriction holes 805c covering different areas, and the blocked areas were 25% and 50%, respectively. The airflow resistance values ​​of the corresponding samples are shown in Table 4:

[0053] Table 4:

[0054] Sample No. 1 2 3 4 5 Turbuhaler Unmodified <![CDATA[Airflow resistance (cmH2O) 0.5 min / L)]]> 0.0987 0.1001 0.1013 0.1024 0.1054 0.1109 0.0873

[0055] As can be seen from Table 4, by blocking part of the inlet limiting hole 805b or 805c on the positioner, the air flow resistance (AFR) of the dry powder inhalation device is increased, and the requirements of The airflow resistance (AFR) of the inhalation device is close to the requirement of uniformity (+ / - 15%).

[0056] Example 4

[0057] Using the Dry powder inhalation device delivery The drug delivered by the inhalation device is provided with an airflow restriction member in the dry powder inhalation device, and the air inlet or the flow restriction hole on the powder outlet of the positioner is partially blocked. The preparation of the drug powder is the same as in Example 1:

[0058] Five dry powder inhalation device samples were designed and prepared. Samples No. 1-5 added an airflow restriction component. The airflow restriction component 15 was a cylindrical pipe with an outer diameter of 4.0 mm and an inner diameter of 2.5 mm. At the same time, samples No. 1-3 covered part of the air inlet 805a, and the blocking areas were 40%, 50%, and 60%, respectively. Samples No. 4-5 covered part of the flow restriction hole 805b, and the blocking areas were 25% and 50%, respectively. The airflow resistance values ​​of the corresponding samples are shown in Table 5:

[0059] Table 5:

[0060] Sample No. 1 2 3 4 5 Handihaler Unmodified <![CDATA[Airflow resistance (cmH2O) 0.5 min / L)]]> 0.1634 0.1697 0.1741 0.1593 0.1603 0.1582 0.0873

[0061] As shown in Table 5, by adding an airflow restriction member to the dry powder inhaler and blocking part of the air inlet or flow restriction hole on the powder outlet of the positioner, the airflow resistance (AFR) of the dry powder inhaler is increased and can meet the requirements of The airflow resistance (AFR) of the inhalation device is close to the requirement of uniformity (+ / - 15%).

[0062] It can be seen from the above embodiments that the airflow resistance value of the dry powder inhalation device can be increased by adding an airflow restriction member to the positioner of the dry powder inhalation device, blocking part of the air inlet or blocking part of the flow limiting hole, and the AFR amplification effect is most obvious when adding an airflow restriction member. When the user inhales the powder, the user holds the interface member 3 in the mouth and inhales forcefully. As a result, a negative pressure is formed between the outlet 14 and the powder outlet portion 805. A portion of the air enters through the air inlet 805a of the powder outlet portion 805, passes through the flow limiting hole 805b to reach the concave cavity 5, and the powdered medicament is lifted up at this time. The powdered medicament passes through the flow limiting hole 805c with the inhaled airflow, further passes through the air outlet 805d, enters the outlet 14, and finally enters the user's oral cavity. Since there is a gap 14a (such as Figure 2 As shown in the figure, when the user inhales, the air passes through the slit 14a through the air outlet 805d and enters the powder outlet 805, resulting in a small airflow resistance. By providing an airflow restriction member between the outlet 14 and the air outlet 805d, the air in the slit can be prevented from entering the powder outlet 805, thereby effectively increasing the airflow resistance. Similarly, blocking part of the air inlet and blocking part of the flow restriction hole also play a role in limiting the inflow of air and achieve the purpose of partially increasing the airflow resistance.

[0063] Since the additional air flow restriction member 15 is on the movement track of the arc wall 13b of the rotating handle 13, in order to prevent the air flow restriction member 15 from hindering the movement of the rotating handle 13, a groove is provided at the tail of the arc wall 13, such as Fig. 9 As shown, it is used to accommodate the air flow restriction member 15.

[0064] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A dry powder inhalation device, comprising a container for powdered medicine defined by two parts that are peelably fixed to each other, the device also comprising a positioner for defining an opening position of the container, and a drive structure for peeling the two parts apart at the opening position to open the container, the device is formed with an outlet connected to the opened container, through which a user can inhale the powdered medicine from the opened container, characterized in that: The positioner is provided with an air flow restriction member located between the positioner and the outlet, the air flow restriction member is a tubular channel, the tubular channel is a cylindrical tubular channel or a truncated cone tubular channel, the air flow restriction member is connected with the positioner and the outlet, and the air flow resistance (AFR) of the dry powder inhalation device is increased; the positioner is provided with a powder outlet portion corresponding to the opening position of the container, the powder outlet portion includes an air inlet at the top, the powder outlet portion is formed with flow restriction holes arranged up and down on the side wall facing the opening position, and the powder outlet portion is provided with a flow restriction hole arranged up and down on the side wall facing the outlet An air outlet hole is formed on the side wall at the same height as the flow limiting hole. Since there is a gap between the outlet and the positioner, when the user inhales, the air passes through the air outlet hole from the gap and enters the powder outlet part, resulting in a small airflow resistance. By arranging an airflow limiting member between the outlet and the air outlet, the air in the gap can be prevented from entering the powder outlet part, thereby effectively improving the airflow resistance. The device includes a rotating handle, which includes an arc-shaped wall with a finger-shaped adjustment piece and a wall extending inward from the arc-shaped wall and having a row of arc-shaped teeth at its terminal, and a groove is provided at the tail of the arc-shaped wall.

2. The dry powder inhalation device according to claim 1, characterized in that: The two components are elongated sheets defining a plurality of spaced apart drug containers along their length, wherein one sheet is a base sheet with a plurality of cavities and the other sheet is a cover sheet, each cavity and the portion of the cover sheet covering the cavity forming a corresponding container.

3. The dry powder inhalation device according to claim 2, characterized in that: The device includes a main wheel with multiple grooves thereon, which is engaged with the drug container so that each groove accommodates a corresponding cavity. The drive structure includes a cover sheet drive structure and a substrate drive structure for peeling off the cover sheet and the substrate at the opening position.

4. The dry powder inhalation device according to claim 3, characterized in that: The main wheel and the cover drive structure as well as the main wheel and the substrate drive structure are connected so that the rotation of the main wheel is related to the rotation of the cover drive structure and the substrate drive structure.

5. The dry powder inhalation device according to claim 1, characterized in that: The positioner forms a powder outlet portion corresponding to the opening position, and an air inlet is arranged on the top of the powder outlet portion to partially cover the air inlet.

6. The dry powder inhalation device according to claim 5, characterized in that: The powder outlet portion is formed with flow limiting holes arranged up and down on the side wall facing the opening position. The flow limiting holes are circular holes with cross grids formed inside the circular holes.

7. The dry powder inhalation device according to claim 6, characterized in that: A grid that obscures a portion of the cross grille.

Images